Sign in
Taking people in New ZealandPhase 3

Tests efimosfermin alfa injection in adults with fatty liver scarring

Tests efimosfermin alfa injection for safety in adults with MASH liver disease.

Key facts

Who runs it
GlaxoSmithKline
Where
Wellington, New ZealandSee the siteAlso in 15 other countries, 153 sites
Registry title
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
Status
Recruiting
Phase
Phase 3
People taking part
1,250 people, planned
Started
12 Dec 2025
Expected to end
24 Mar 2028
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Efimosfermin Alfa
  • Placebo
Record updated
17 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 75 with known or suspected MASH (a fatty liver disease) with scarring of the liver. It tests the safety of efimosfermin alfa.

Age
18 to 75 years
Sex
Men and women can join.
Disease stage
Known or suspected MASH with liver scarring (fibrosis), stage F2 or F3. No cirrhosis.

Main reasons for not taking part

  • Other chronic liver disease, cirrhosis or decompensated liver disease
  • Excessive alcohol use for 3 months or more in the past 12 months
  • HIV or hepatitis B, C, D or E infection
  • Abnormal liver or kidney blood tests, or HbA1c of 9.0% (75 mmol/mol) or more
  • Alpha-fetoprotein of 20 ng/mL or more

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Able and willing to understand and sign a written informed consent form (ICF) that must be obtained prior to the initiation of study procedures
  • Age >=18 through <=75 years at enrolment
  • History or presence of 2 or more of the 5 components of metabolic syndrome per American Heart Association definition
  • History or presence of known or suspected MASH with evidence of fibrosis

Who cannot take part

  • Chronic liver disease from any other cause including, but not limited to, alcoholic liver disease; evidence of portal hypertension; viral hepatitis, or any history or evidence of cirrhosis; or decompensated liver disease such as clinical ascites, bleeding gastroesophageal varices, hepatorenal syndrome, or hepatic encephalopathy prior to Screening or Day 1
  • Current or history of excessive alcohol intake for >=3 months within the 12-month period prior to Screening
  • Model for End-Stage Liver Disease (MELD) 3.0 score >=12 unless the score is elevated in the absence of liver dysfunction (eg, Gilbert's syndrome)
  • Known co-infection with any of the following: a. Human immunodeficiency virus; b. Hepatitis B virus; c. Hepatitis C virus (HCV); d. Hepatitis D virus; or e. Hepatitis E virus
  • ALT or AST >=5 × upper limit of normal (ULN)
  • Total bilirubin (BILI) >=1.3 milligram per deciliter (mg/dL). Individuals with documented Gilbert's syndrome may be enrolled if they experienced an isolated increase in total BILI of >=1.3 mg/dL and direct BILI is <=20% of total BILI; otherwise, the individual will be excluded
  • Serum albumin <=3.5 grams per deciliter (g/dL)
  • International normalized ratio (INR) >=1.3 not due to therapeutic anticoagulation. Individuals receiving chronic anticoagulant treatment with higher INR values may be enrolled at the discretion of the Investigator and Study Medical Monitor
  • Alkaline phosphatase (ALP) >=2 × ULN
  • Platelet (PLT) count <140 000 per (/) cubic millimeter (mm\^3); individuals with a PLT count between 110,000/mm\^3 and 140,000/mm\^3 may be enrolled after discussion with the Study Medical Monitor
  • Serum creatinine >=1.5 mg/dL or creatinine clearance <=60 milliliter (mL)/minute (min)/1.73 square meter by Chronic Kidney Disease Epidemiology Collaboration equation
  • HbA1c >=9.0%
  • Alpha-fetoprotein >=20 nanogram per milliliter (ng/mL)
  • Phosphatidylethanol (PEth) >=80 nanogram per milliliter (ng/mL) at Screening

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

This trial is currently available in New Zealand.

Also in 15 other countries, 153 sites

  • WellingtonHospital not named in the registryContact: Stephen Inns (principal investigator)Taking people

About the trial

What the trial wants to find out

This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH with fibrosis consistent with stage F2 or F3.

The 3 groups in the trial

  • Efimosfermin Alfa Dose Level 1Treatment being tested

    Participants randomized to this group will receive Efimosfermin Alfa at dose level 1

    Treatment: Efimosfermin Alfa

  • Efimosfermin Alfa Dose Level 2Treatment being tested

    Participants randomized to this group will receive Efimosfermin Alfa at dose level 2

    Treatment: Efimosfermin Alfa

  • PlaceboPlacebo, for comparison

    Participants randomized to this group will receive Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)
Plain-language title
Tests efimosfermin alfa injection in adults with fatty liver scarringGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT07221188, who can take part
Record updated
17 September 2026